Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRVS |
---|---|---|
09:32 ET | 449 | 2.17 |
09:36 ET | 100 | 2.195 |
09:38 ET | 200 | 2.195 |
09:39 ET | 3399 | 2.1405 |
09:50 ET | 1900 | 2.1401 |
09:56 ET | 100 | 2.16 |
10:12 ET | 274 | 2.17 |
10:14 ET | 740 | 2.16 |
10:21 ET | 1000 | 2.15 |
10:24 ET | 100 | 2.165 |
10:26 ET | 244 | 2.17 |
10:30 ET | 4660 | 2.17 |
10:32 ET | 150 | 2.17 |
10:35 ET | 1094 | 2.17 |
10:39 ET | 2340 | 2.17 |
10:51 ET | 100 | 2.165 |
11:04 ET | 3481 | 2.12 |
11:06 ET | 100 | 2.14 |
11:09 ET | 100 | 2.145 |
11:13 ET | 100 | 2.145 |
11:20 ET | 750 | 2.15 |
11:29 ET | 2068 | 2.1307 |
11:31 ET | 100 | 2.135 |
11:45 ET | 2100 | 2.13 |
11:49 ET | 300 | 2.13 |
11:58 ET | 150 | 2.13 |
12:00 ET | 600 | 2.1222 |
12:18 ET | 7827 | 2.11 |
12:41 ET | 100 | 2.105 |
12:43 ET | 333 | 2.105 |
12:45 ET | 100 | 2.11 |
12:48 ET | 3616 | 2.11 |
12:50 ET | 4084 | 2.12 |
12:54 ET | 600 | 2.1253 |
12:56 ET | 100 | 2.13 |
12:59 ET | 700 | 2.135 |
01:21 ET | 277 | 2.14 |
01:44 ET | 533 | 2.1381 |
01:46 ET | 200 | 2.14 |
01:48 ET | 150 | 2.14 |
01:53 ET | 100 | 2.15 |
01:57 ET | 3981 | 2.12 |
02:04 ET | 100 | 2.125 |
02:15 ET | 400 | 2.1192 |
02:22 ET | 2372 | 2.115 |
02:31 ET | 433 | 2.12 |
02:38 ET | 211 | 2.13 |
02:44 ET | 100 | 2.1 |
02:45 ET | 709 | 2.115 |
02:47 ET | 100 | 2.115 |
02:49 ET | 433 | 2.1 |
02:58 ET | 100 | 2.1 |
03:12 ET | 600 | 2.0938 |
03:20 ET | 200 | 2.1 |
03:21 ET | 300 | 2.0999 |
03:23 ET | 8434 | 2.075 |
03:36 ET | 2257 | 2.07 |
03:38 ET | 300 | 2.07 |
03:39 ET | 900 | 2.0799 |
03:41 ET | 200 | 2.075 |
03:50 ET | 200 | 2.07 |
03:52 ET | 200 | 2.08 |
03:54 ET | 676 | 2.085 |
03:56 ET | 100 | 2.08 |
03:57 ET | 100 | 2.07 |
03:59 ET | 1899 | 2.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corvus Pharmaceuticals Inc | 133.9M | -4.0x | --- |
aTyr Pharma Inc | 134.6M | -2.1x | --- |
Cardiff Oncology Inc | 131.9M | -3.3x | --- |
RAPT Therapeutics Inc | 128.4M | -1.2x | --- |
Cytodyn Inc | 139.4M | -2.5x | --- |
Kiora Pharmaceuticals Inc | 126.7M | -3.1x | --- |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $133.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-0.51 |
Book Value | $0.79 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.